SecBot SecBot
8-K ·Filed Aug 6, 2026

EWTX

Edgewise Therapeutics, Inc.
MIXED
Impact 7/10
Horizonmonths Processed3mo ago SEC0001104659-26-091671
8-K Item 2.02: Earnings release
Actionable Insight ◆ Mixed

The Servier deal removes the muscular dystrophy pipeline risk and provides a massive cash infusion, but the company is now a single-asset cardiovascular biotech with no approved products. The key catalyst is the Phase 3 start for EDG-7500 in HCM in Q4 2026. Monitor for milestone payments from Servier (up to $1.1B) and any early efficacy/safety signals from the EDG-7500 Phase 3 program.

DirectionMixed
Confidencehigh
Horizonmonths

Drugs in focus

EWTX drug pipeline →

EDG-15400

● Neutral Named in this 8-K
Impact
Phase
Phase 1
Time to market
Unlikely before 2029-2030 at earliest — Phase 1 data pending, Phase 2 not yet initiated, and HFpEF Phase 3 trials typically take years
Next catalyst
None dated

What to watchEDG-15400 is too early-stage to drive meaningful share price moves in the near term. Watch for the Phase 2 HFpEF trial initiation (expected H2 2026) and eventual Phase 2 data (H1 2027). For EWTX, the more impactful near-term catalyst is the EDG-7500 Phase 3 trial initiation in HCM (Q4 2026). EDG-15400 is a pipeline extension story for now.

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$44.42
T+0 close · Aug 6, 2026 · via day close
Latest settled
−12.43%
T+60 · $38.90
Vs SPY
−10.76%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Aug 6 $44.42entry
  2. T+1 · 3mo ago −2.03%α −2.64% · $43.52
  3. T+5 · 3mo ago −2.79%α −4.00% · $43.18
  4. T+20 · 3mo ago −5.56%α −6.16% · $41.95
  5. T+60 · 18d ago −12.43%α −10.76% · $38.90
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Edgewise Therapeutics reported Q2 2026 net loss of $0.53/share, a 12.2% miss vs consensus of $-0.47, with no revenue. The quarter was dominated by the July 2026 completion of the sevasemten sale to Servier for $1.55B upfront (up to $2.65B total), transforming the balance sheet to a pro-forma $2.01B cash position and pivoting the company to a pure-play cardiovascular focus. Positive Phase 2 CIRRUS-HCM data for EDG-7500 supports a planned Phase 3 start in Q4 2026, but the company remains pre-revenue with widening operating losses as it funds the new pipeline.

Key Financial Metrics

EPS
−$0.53
est −$0.47 · -12.8%
Revenue
$0.00
est $0.00
Rating
miss

Key Facts

  • Net loss per share was $-0.53 for Q2 2026, compared to $-0.34 in Q2 2025, a 55.9% YoY increase in net loss.
  • EPS of $-0.53 missed consensus of $-0.47 by 12.2%.
  • Completed sale of sevasemten and muscular dystrophy business to Servier for $1.55B upfront cash (up to $2.65B total) in July 2026.
  • Pro-forma cash balance post-sale is approximately $2.01B before taxes and transaction costs, up from $460.7M at quarter-end.
  • Positive 12-week Phase 2 CIRRUS-HCM data for EDG-7500 announced; Phase 3 initiation expected in Q4 2026.
  • R&D expenses rose 41.7% YoY to $47.5M, driven by EDG-7500, EDG-15400, and MESA extension study activity.
  • Company has no revenue and is transitioning to a cardiovascular-focused biopharmaceutical company.

Financial Impact

Q2 net loss of $57.3M widened 58.7% YoY from $36.1M; pro-forma cash of ~$2.01B post-Servier deal provides >8 years of runway at current burn rate.

net losscash positionR&D expenses

Risk Factors

  • Single-asset dependency on EDG-7500 for HCM, with no approved products or revenue.
  • Phase 3 clinical risk for EDG-7500; positive Phase 2 data may not replicate.
  • Operating losses are widening as R&D spend increases for the cardiovascular pipeline.
  • No guarantee of receiving the $1.1B in milestone payments from Servier.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
84% bullish (19 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001104659-26-091671
Document: tm2621653d1_8k.htm0001104659-26-091671
Document: 0001104659-26-091671-index-headers.html0001104659-26-091671
Document: 0001104659-26-091671-index.html0001104659-26-091671
Document: 0001104659-26-091671.txt0001104659-26-091671
8-K Data (Synthetic)0001104659-26-091671

Track record

14 reports on EWTX

Performance horizon

The track record builds as more bullish or bearish reports settle.

Filters
  1. Nov 16, 2026today 144 Neutral 1/10 Entry price pending
  2. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $44.09 Now $43.68 −0.93% settles Feb 12
  3. Nov 5, 202611d ago SC 13G/A Neutral 2/10 Entry $38.87 Now $43.68 +12.37% settles Feb 3
  4. Nov 4, 202612d ago 8-K Neutral 5/10 Entry $38.87 Now $43.68 +12.37% settles Feb 3
  5. Nov 2, 202614d ago Institutional Cluster Neutral 3/10 Entry $37.68 Now $43.68 +15.92% settles Feb 1
  6. Aug 14, 202613w ago Insider Cluster Neutral 4/10 Entry $44.04 to $46.53 Now $43.68 −0.82% ▲ +5.65% +8.60% vs SPY
  7. Aug 14, 202613w ago Insider Cluster Neutral 3/10 Entry $44.04 to $46.53 Now $43.68 −0.82% ▲ +5.65% +8.60% vs SPY
  8. Aug 6, 202614w ago 8-K Mixed 7/10 Viewing Entry $44.42 to $38.90 Now $43.68 −1.67% ▼ −12.43% −10.76% vs SPY
  9. Jul 13, 202618w ago 8-K Bullish 7/10 Entry $41.27 to $40.02 Now $43.68 +5.84% ▼ −3.03% −7.02% vs SPY
  10. Jun 1, 202624w ago 8-K Bullish 8/10 Entry $40.26 to $44.21 Now $43.68 +8.49% ▲ +9.81% +8.58% vs SPY
Showing 10 of 14

US Market Status

Market Closed · Opens Wed (10h 33m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 6, 2026